Advanced Malignant Solid Tumors Clinical Trial
Official title:
A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-415S1 in Patients With Advanced Malignant Solid Tumor
Verified date | July 2023 |
Source | Hutchmed |
Contact | Ronghua Zhang |
Phone | +86 1526711056 |
ronghuaz[@]hutch-med.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The objective of this study is to evaluate the safety, tolerability and PK profile of HMPL-415S1 and determine MTD and/or RP2D in patients with advanced malignant solid tumor.
Status | Recruiting |
Enrollment | 81 |
Est. completion date | June 30, 2026 |
Est. primary completion date | May 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: All the following conditions must be met for enrollment: 1. Fully understand this study and voluntarily sign the ICF; 2. Dose escalation Patients with advanced malignant solid tumor confirmed by histopathology or cytology, who have failed, been intolerant or unavailable to, or have none standard treatment for various reasons; Dose expansion phase: Patients with advanced malignant solid tumor confirmed by histopathology or cytology, who have failed, been intolerant or unavailable to, or have none standard treatment for various reasons, carrying aberrant activating mutations in the KRAS pathway; 3. Presence of at least one measurable lesion (RECIST 1.1 criteria); 4. Eastern Cooperative Oncology Group (ECOG) performance status = 1 point; 5. Life expectancy = 12 weeks as judged by the investigator; 6. Male of childbearing potential and their heterosexual partners of childbearing potential must agree to use effective methods of contraception. Exclusion Criteria: A patient may not participate in this study if any of the following conditions apply: 1. Patients who priorly received SHP2 inhibitors; 2. Receiving the approved systemic antitumor treatment within 4 weeks prior to the first dose, including: chemotreatment, targeted treatment, immunization treatment, biological treatment, etc. (wash-out for 2 weeks for hormone treatment or traditional chinese medicine and chinese patent medicine with clear antitumor indications); 3. Have been in the treatment period of other interventional clinical studies (including small molecule chemicals and large molecule antibodies) within 4 weeks prior to the first dose. If participating in a non-interventional clinical study (eg, epidemiological study), you can enroll in this study; if already in the survival follow-up period of an interventional clinical study, you can enroll in this study. 4. Major surgery or radical radiotreatment (except palliative radiotreatment for metastases to bone lesions) within 4 weeks prior to first dose. 5. Central nervous system (CNS) malignant tumor or known CNS metastasis; 6. Having multiple factors that affect the absorption, distribution, metabolism or excretion of orally administered drugs (such as inability to swallow drugs, frequent vomiting, chronic diarrhoea, etc.); 7. Any other disease, metabolic abnormality, physical examination abnormal, or clinically significant laboratory test abnormality that, in the judgment of the investigator, would compromise patient compliance or give reason to suspect that the patient has a disease or condition that would compromise the interpretation of study results or place the patient at high risk. |
Country | Name | City | State |
---|---|---|---|
China | Zhongshan Hospital Fudan University | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Hutchmed |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the safety, tolerability, and determine the maximum tolerated dose (MTD) and/or RP2D of HMPL-415S1 as a single oral agent in advanced malignant solid tumor | Occurrence of Dose Limiting Toxicities (DLTs) During the DLT Observation Period | from Cycle 0Day1 up to Cycle1Day28 (each cycle is 28 days). | |
Secondary | To investigate the pharmacokinetic (PK) profile of oral HMPL-415S1 | Plasma peak concentration of HMPL-415S1 (Cmax). | from pre-dose to day 5 of cycle 0. (cycle 0 contains 5 days). | |
Secondary | AUCinf (Cycle 0 ) of HMPL-415S1 | AUCinf: area under the concentration vs. time curve from zero to infinity after single (first)dose. | from pre-dose to day 5 of cycle 0. (cycle 0 contains 5 days). | |
Secondary | AUC(0-tlast) (Cycle 0 ) of HMPL-415S1 | AUC from time zero to the last data point. | from pre-dose to day 5 of cycle 0. (cycle 0 contains 5 days). | |
Secondary | Objective Response Rate (ORR) | Percentage of patients with Complete Response(CR) or Partial Response(PR) as the best response evaluated in accordance with RECIST 1.1. | From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years). | |
Secondary | Disease control rate (DCR) | the proportion of patients with CR or PR or stable disease (SD) as the best response, and the duration of SD needs to be =6 weeks. | From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years). | |
Secondary | uration of response (DoR) | as the time from the first appearance of CR or PR to PD or death for any reason (whichever comes first), in the patients with objective response. | From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years). | |
Secondary | Time to response (TTR) | the time from the first dose of HMPL-415S1 to the first objective response. | From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years). | |
Secondary | Progression-free survival (PFS) | time from the first dose of study treatment to PD or death for any reason, whichever comes first. | From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years). | |
Secondary | Overall survival (OS) | time from the first dose of study treatment to death for any reason. | From baseline to final assessment at end of safety follow-up visit (up to a maximum of approximately 3 years). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00728468 -
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
|
Phase 1 | |
Completed |
NCT00445458 -
A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00768469 -
Study Evaluating Safety And Tolerability, Solid Tumor
|
Phase 1 | |
Recruiting |
NCT04226066 -
Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04908046 -
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06464055 -
A Study of GQ1010 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06231550 -
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05383703 -
Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor
|
Phase 1 | |
Recruiting |
NCT05773937 -
A Clinical Study of 9MW2821 in Advanced Malignant Solid Tumors
|
Phase 1 | |
Completed |
NCT04328506 -
Bioequivalency Study of CM082 Tablet in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00958724 -
Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05949775 -
Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors
|
N/A | |
Terminated |
NCT02045095 -
A Dose Escalation Study of MLN7243 (TAK-243) in Adult Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00884845 -
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05277454 -
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
|
Phase 1 | |
Active, not recruiting |
NCT03792958 -
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT00997360 -
Study of PKI-179 Administered Orally to Subjects With Solid Tumors
|
Phase 1 | |
Completed |
NCT04126668 -
A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT05338957 -
A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.
|
Phase 1/Phase 2 | |
Recruiting |
NCT03047811 -
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
|
N/A |